Cancer - Bladder
Bladder Cancer – June 2022
A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer
PLOS x Published: June 16, 2022 https://doi.org/10.1371/journal.pone.0266371
Ahmed Abdelgawad ,Abdelwahab Hashem,Ahmed Mosbah ,Laila A. Eissa

Purpose
Higher levels of serum 25-hydroxyvitamin D 25(OHD) are associated with better prognosis in breast and colorectal cancer. However, the evidence is still inconclusive for bladder cancer (BC). Herein, we investigated the diagnosis and prognosis roles of serum levels of 25(OHD) in suspected BC patients presented by hematuria.
Methods
This prospective cohort study involved suspected patients of BC presented with hematuria. Patients were evaluated by CT urogram, office cystoscopy and urine cytology with subsequent inpatient biopsy for positive findings. Baseline blood samples were collected for measurement of 25(OHD) by electrochemiluminescence binding assay at the time of diagnosis. Patients with non-muscle-invasive BC (NMIBC) underwent transurethral resection of bladder tumor (TURBT) and adjuvant intravesical chemotherapy or BCG instillation. Patients were followed up for their recurrence status during 10 to 24 months. Recurrence was defined as the first time of NMIBC pathological relapse during the follow up period.
Results
A total of 115 patients were included in the final analysis. Patients had proven pathological BC (64 with NMIBC, and 20 with muscle invasive) and 31 patients were considered as control group. Controls were those patients with BC-free workup (including cytology, cystoscopy, and upper tract imaging). BC group showed a lower level of 25(OHD) than control group 16.47±5.88 versus 28.99±3.19 ng/mL (p<0.001). In addition, muscle invasive group also showed a lower level than NMIBC group 13.17±4.5 versus 17.49±5.04 ng/mL (P = 0.003). During the follow-up period of, tumor recurrence occurred in 16 (25%) of NMIBC patients. The baseline 25(OHD) were decreased in patients who experienced early recurrence; without being statistically significant (15.99 ± 5.17 vs. 18.38 ± 5.14 ng/mL; p = 0.08). 25(OHD) deficiency/insufficiency occurred in 5 (16.1%) and 64 (76.2%) in control and BC patients, respectively, (odds-ratios (OR): 2.13; 95% confidence intervals (CI), 1.52–2.99; P < 0.0001).
Conclusion
Serum 25(OHD) is significantly decreased in BC patients especially those with tumor muscle invasive group. However, the baseline serum 25(OHD) does not predict the recurrence in the NMIBC patients.
📄 Download the PDF from Vitamin D Life
Vitamin D Life - Meta-anayses of Bladder Cancer
This list is automatically updated
{category}
All Bladder Cancer studies in Vitamin D Life
{category}
See also All items in category Cancer and Vitamin D items
See also web
Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort - June 2021 📄 PDF
Low Plasma 25-Hydoxyvitamin D at Diagnosis Predicts Poor Outcomes in Patients with Bladder Cancer: A Prospective Cohort Study - July 2020 https://doi.org/10.1080/01635581.2020.1737150
5 out of 7 studies of Bladder Cancer and Vitamin D found an association Science Daily Nov 2016
LOW SERUM 25-HYDROXYVITAMIN D IS ASSOCIATED WITH INCREASED BLADDER CANCER RISK: A SYSTEMATIC REVIEW AND EVIDENCE OF A POTENTIAL MECHANISM - Jan 2019;
- "Low vitamin D levels were associated with bladder cancer risk in 5/6 of the studies"
- Bladder cells appear to need to activate Vitamin D locally , doi: 10.1016/j.jsbmb.2019.01.002